Confirmation No.

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT

: Kazuo Ando, et al.

EXAMINER

SERIAL NO.

ART UNIT

FILED

PAPER NO

FOR

: 1-[2-(Hydroxyphenyl)-2-Hydroxyethyl]-Piperidin-4-ol Compounds As NMDA

Receptor Antagonists

Statement as Provided by 37 CFR 1.97(b)

Mail Stop: Amendment Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

Dear Sir:

The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of the first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

It is requested that the references listed on the attached form PTO-SB-08A be included in the "References Cited" portion of any patent issuing from this application (MPEP § 1302.12).

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. §1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

10/575383 IAP15 Rec'd PCT/PTO 07 APR 2006

-2-

PC25145A

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Respectfully submitted,

Dated:

David R. Kurlandeky

Registration No. 41,505

Pfizer, Inc.

2800 Plymouth Road Ann Arbor, MI 48105

Telephone: (734) 622-7304 Facsimile: (734) 622-1553

CERTIFICATE OF MAIN Applicant(s): Kazuo Ando, et	Docket No. PC26145A		
Serial No.	Filing Date	Examiner	Group Art
Invention:			
1-[2-(Hydroxyphenyl)-2-Hydr	oxyethyl]-Piperidin-4-ol Compo	unds As NMDA Receptor Anta	agonists
I hereby certify that this	Patent Application Under 35 U.S	S.C. § 371 (Identify type of correspondence)	
Is being deposited with the Un	nited States Postal Service "Exp	oress Mail Post Office to Addre	ssee" service under
on April 7 (Date)	ddressed to: Commissioner for	r Patents, P.O. Box 1450, Ald	exandria, VA 22313-1450
			A. Zerby
		Signature of Person	Person Mailing Correspondence) Mailing Correspondence 394292US Mailing Label Number)

IAP15 Rec'd PCT/PTO 07 APR 2006

Confirmation No.

PTO/SB/08A (07-05) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitu	ute for form 1449/P	то	-	Complete if Known		
				Application Number	1075753	583
INIE		OND	ISCLOSURE	Filing Date		
• • • •				First Named Inventor	Kazuo Ando, et al.	
STA	·		APPLICANT	Art Unit		
(Use as many sheets as necessary)			s necessary)	Examiner Name		
Shoot	1	of.	3	Attorney Docket Number	PC26145A	

U. S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant			
		Number-Kind Code ^{2 (F known)}			Figures Appear			
		^{US-} 5,710,168	01-20-1998	Bertrand L. Chenard				
		US-						
		US-						
	1	US-						
		US-		·				
		US-						
	 	US-			-			
		US-						
	1	US-						
	1	US-						
		US-						
	-	US-						
	 	US-						
		US-						
		US-						
· · · · · · · · · · · · · · · · · · ·	 	US-						
	 	US-						
	 	US-						
		US-						

			IGN PATENT DOCL		T =	
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	i
muais	NO.	Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant or Cited Document	Or Relevant Figures Appear	Т
	1	WO1996/06081 A1	02-29-1996	Pfizer Inc		
		WO 1997/23216 A1	07-03-1997	Warner-Lambert Co.		
		WO 1999/21539 A1	05-06-0199	Warner-Lambert Co.		
						L

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

IAP15 Rec'd PCT/PTO 07 APR 2006

Confirmation No.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	te for form 1449/PTO			Complete if Known				
Substitut	te 101 101111 1445/F1O			Application Number		10/5753	583	
INF	ORMATION	DIS	CLOSURE	Filing Date				
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Kazuo Ando, et al.			
				Art Unit				
	(Use as many she	ets as ne	ecessary)	Examiner Name		<u> </u>		
Sheet	2	of	3	Attorney Docket Number	PC26145A		フ	

	1 60	NON PATENT LITERATURE DOCUMENTS	1
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		S. BOYCE, et al., "Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn " Neurpharmacology, 199, pp 611-623, Vol. 38, No. 5	
		I CAVERO, et al., "Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias", Expert Opinion on Pharmacotherapy, 2000, pp 947-973, Vol. 1, No. 5	
		K. FINLAYSON, et al., "[3H]Dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen", Euro J Pharmacology, 2001, pp 147-148, Vol. 430, No. 1	
		D. M. GRENNAN, et al., "Rheumatoid Arthritis", Textbook of Pain, 1994, pp 397-407	
		J. H. HOGUE, et al., "Pathophysiology and First-Line Treatment of Osteoarthritis", The Annals of Pharmacotherapy, 2002, pp 679-686, Vol. 36	
		J. LEVINE, et al., "Inflammatory Pain", Textbook of Pain, 1994, pp 45-56	
		C. MCCARTHY, et al., "Osteoarthritis", Textbook of Pain, 1994, pp 387-396	
		R. A. MEYER, et al., "Peripheral Neural Mechanisms of Nociception", Textbook of Pain, 1994, pp 13-55	
		M. J. MILLAN, et al., "The Induction of Pain: An Integrative Review", Progress in Neurobiology, 1999, pp 1-64, Vol. 57	
		C. J. WOOLF, et al., "Implications of Recent Advances in the Understanding of Pain Pathophysiology for the Assessment of Pain in Patients", Pain Supplement, 1999, pp S141-S147, No. 6	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IAP15 Rec'd PCT/PTO 07 APR 2006

Confirmation No.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	te for form 1449/PT	^			Complete if Known		.
Gubsinu	(C 101 101111 1443/F 1	O		Application Number		10/5753	8
INF	DRMATIO	N DIS	CLOSURE	Filing Date			
STA	TEMENT	BY AF	PLICANT	First Named Inventor	Kazuo Ando, et al.		
				Art Unit			
	(Use as many :	sneets as nee	essary)	Examiner Name			
Sheet	3	of	3	Attorney Docket Number	PC26145A		1

,	NON PATENT LITERATURE DOCUMENTS	
Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C. J. WOOLF, et al., "Neuronal Plasticity: Increasing the Gain in Pain", Science, 2000, pp 1765-1768, Vol. 288	
	C. J. WOOLF, et al., "Neuropathic pain:aetiology, symptoms, mechnisms, and management", The Lancet, 1999, pp 1959-1964, Vol. 353, No. 9168	
	·	
	,	
	Cite No.1	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. C. J. WOOLF, et al., "Neuronal Plasticity: Increasing the Gain in Pain", Science, 2000, pp 1765-1768, Vol. 288 C. J. WOOLF, et al., "Neuropathic pain:aetiology, symptoms, mechnisms, and management", The

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.